HSBC Cuts Zoetis Inc. (ZTS)’s Price Target To $140 From $180, Keeps Buy Rating
Affected assets and topics
Why it matters
HSBC lowered the price target for Zoetis Inc. (ZTS) to $140 from $180, while maintaining a Buy rating, indicating a decrease in expected stock value but still a positive outlook.
Article tone
Expected market reaction
Market impact analysis based on bearish sentiment with 71% confidence.
Evidence trail
Evidence
AI provenance
Technical identifiers
- Provider tag
- groq-llama-3.1-8b-instant
- Analysis version
- groq-llama-3.1-8b-instant
- Article id
- 22025
Original source
Zoetis Inc. (NYSE:ZTS) is among the 11 Most Oversold S&P 500 Stocks Heading into 2026. On December 10, HSBC slashed its price target on the stock to $140 from $180, as part of the firm’s broader overview of pharmaceutical stocks for 2026. However, the investment bank maintained its earlier Buy rating for the shares. It […]
Read the full article on Yahoo Finance
Original article published by Yahoo Finance on December 13, 2025. Analysis and insights provided by AnalystMarkets AI.